Sponsor
- Home
- Your Messages
-
Smartest Doc
Test your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
We invite you to take the "Autoimmune diseases Quiz"
>> Live Leaderboard
New! PHYSICIAN REVIEW
Assess your general knowledge at the topic level with your personalized scorecard.
Thousands of multiple-choice questions pinpoint your areas of expertise and prep you for exams.
- Physician Jobs (1284)
- More
- Other Specialty
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma The Journal of Dermatology, 05/10/2012
Wada H et al. – Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with cutaneous T–cell lymphoma (CTCL), warranting further investigation.
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor